Craving respiratory dominance, AstraZeneca inks $2.1B deal for Almirall’s lung meds

Tracy Staton AstraZeneca has agreed to pay $ 875 million up front–and up to $ 2.2 billion total, with milestones–for Almirall's respiratory portfolio. The deal brings ...

Sanofi, Regeneron pay $67.5M for a regulatory shortcut in blockbuster PCSK9 race with Amgen

John Carroll Sanofi and Regeneron just stole a march on Amgen in the race to get their PCSK9 cardio drug through the FDA and onto the market. The two companies revealed Wednesday evening ...

Sanofi and Regneron prep their cardio contender for FDA review after a Phase III sweep

Damian Garde Sanofi and Regeneron are heading to the FDA with a potential blockbuster cardiovascular treatment, touting positive results from a slew Phase III trials in which the drug ...

Want to claim a name? FDA needs your input on locking down brand monikers

Justin Heifetz Advertising experts have a few tricks up their sleeves when concocting a drug's proprietary name–like Zytiga, Xtandi and Xeljanz–that might thrust the ...

Don’t get too excited, investors: GSK has no near-term plans for consumer health spinoff

Carly Helfand Let GlaxoSmithKline be clear: It's open to spinning off its consumer healthcare division at some nebulous point in the future. But it's not happening anytime soon. FiercePharma ...

UPDATED: Amgen axing up to 2,900 staffers, shuttering sites in major restructuring

John Carroll Bracing for an expensive round of late-stage studies and potential drug launches as it ramps up work on a slate of new biosimilars, Amgen reported Tuesday evening that ...

Sarepta’s boardroom intrigue clouds a promising drug’s future

Damian Garde After Sarepta Therapeutics' former head scientist blamed his swift ouster on "serious disagreements" with CEO Chris Garabedian, the company has moved to limit ...

J&J, Pharmacyclics celebrate yet another nod for leukemia med Imbruvica

Tracy Staton Johnson & Johnson's new blood cancer drug Imbruvica (ibrutinib) is on a roll. The FDA just armed the drug with a new indication in chronic lymphocytic ...

China sets trial date for GSK-tied investigators, says it will be ‘open’

Carly Helfand China will try two private investigators tied to GlaxoSmithKline's operations there in just over a week on charges of illegally purchasing personal information about ...

Quark’s RNAi treatment misses the mark in a Phase II kidney trial

Damian Garde Quark Pharmaceuticals' gene-silencing treatment for kidney transplant complications missed its primary endpoint in a Phase II trial, possibly jeopardizing a deal with ...

UPDATED: Targacept’s litany of trial failures continues with yet another flop

John Carroll On Monday, Targacept reported that its midstage effort aimed at salvaging its lead drug flopped. Once partnered with AstraZeneca, which saw four late-stage studies for ...

Merck spokeswoman: Sales layoffs to hit PA-based field reps

Tracy Staton The job-cutting ax has come out for Merck's U.S. field force, as part of a move to cut 600 positions by August.  FiercePharma News
Page 1 of 1212345...10...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS